Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice

Phillip F. Giannopoulos | Jian Chiu | Domenico Praticò

Alzheimer’s Center at Temple, Lewis Katz Temple University School of Medicine, Philadelphia, PA, USA

Correspondence
Domenico Praticò, Scott Richards North Star Charitable Foundation Chair, Lewis Katz Temple University School of Medicine, Philadelphia, PA, USA.
Email: praticod@temple.edu

Funding information
This study was supported in part by a grant from the Scott Richards North Star Charitable Foundation

Summary
The 5-lipoxygenase (5LO) is a source of inflammatory leukotrienes and is upregulated in Alzheimer’s disease and related tauopathies. However, whether it directly modulates tau phosphorylation and the development of its typical neuropathology in the absence of Aβ or is a secondary event during the course of the disease pathogenesis remains to be fully elucidated. The goal of this study was to evaluate the effect that pharmacologic blockade of this inflammatory pathway has on the phenotype of a transgenic mouse model of tauopathy, the P301S mice. Starting at 3 months of age, P301S mice were randomized to receive zileuton, a specific 5LO blocker, for 7 months; then, its effect on their behavioral deficits and neuropathology was assessed. Inhibition of leukotrienes formation was associated with a reduction in tau phosphorylation and an amelioration of memory and learning as well as synaptic integrity, which were secondary to a downregulation of the cdk5 kinase pathway. Our results demonstrate that the 5LO enzyme is a key player in modulating tau phosphorylation and pathology and that blockade of its enzymatic activity represents a desirable disease-modifying therapeutic approach for tauopathy.

KEYWORDS
leukotrienes, neuroinflammation, rodent behavior, tauopathy, transgenic mice

1 | INTRODUCTION

Alzheimer’s disease (AD) is a chronic neurodegenerative condition with dementia affecting approximately 6%–8% all person aged >65. From a pathologic point of view, AD is characterized by the progressive accumulation of insoluble intra- and extracellular Aβ peptides and intracellular aggregates of highly phosphorylated microtubule-associated protein tau (Giannopoulos & Praticò, 2015). Human tauopathies, which include among other diseases progressive supranuclear palsy, Pick’s disease, and corticobasal degeneration, are neurodegenerative conditions that share with AD the formation and progressive accumulation of neurofibrillary tangles, which result from the deposition of hyperphosphorylated tau protein (Arendt, Stieler & Holzer, 2016; Spillantini & Goedert, 2013). While their etiology remains unknown, consistent data have emerged in the literature linking neuroinflammatory pathways to the neurodegenerative processes characteristic in these diseases. However, what remains still to be fully established is the origin of these inflammatory reactions and whether they play a functional role or are just secondary events in their pathogenesis (Ishizawa & Dickson, 2001; Laurent et al., 2007).

The 5-lipoxygenase (5LO) is a pro-inflammatory enzyme that by oxidizing free and esterified fatty acids produces potent bioactive lipids, most of which are grouped under the name of leukotrienes (LTs) (Giannopoulos, Chu et al., 2014; Giannopoulos, Joshi & Praticò, 2014). The protein is widely expressed in the central nervous system, particularly in areas reared to be involved in cognitive function. The 5LO pathway is also thought to be involved in the pathogenesis of multiple inflammatory and neurodegenerative diseases, including AD and other tauopathies. Therefore, the present study was designed to evaluate the impact of pharmacologic blockade of the 5LO enzyme on the phenotype of a transgenic mouse model of tauopathy, the P301S mice. Starting at 3 months of age, P301S mice were randomized to receive zileuton, a specific 5LO blocker, for 7 months; then, its effect on their behavioral deficits and neuropathology was assessed. Inhibition of leukotrienes formation was associated with a reduction in tau phosphorylation and an amelioration of memory and learning as well as synaptic integrity, which were secondary to a downregulation of the cdk5 kinase pathway. Our results demonstrate that the 5LO enzyme is a key player in modulating tau phosphorylation and pathology and that blockade of its enzymatic activity represents a desirable disease-modifying therapeutic approach for tauopathy.
system, where it localizes to both neuronal and glial cells. Previously, our group has demonstrated a role for SLO in the development of the AD-like phenotype of APP transgenic mice and related tauopathy as well as the triple transgenic mice, which are known to develop both Aβ plaques and tau tangles (Chu, Giannopoulos, Ceballos-Diaz, Golde & Pratico, 2012; Chu, Li & Pratico, 2013; Giannopoulos, Chu et al., 2014; Giannopoulos et al., 2015; Giannopoulos, Joshi & Pratico, 2014; Joshi, Chu & Pratico, 2013). More recently, we showed that genetic deficiency for SLO rescued behavioral deficits and tau phosphorylation, as well as synaptic pathology and neuroinflammation in the P301S mice (Vagnozzi, Giannopoulos & Pratico, 2017). Taken together, these findings support the novel hypothesis that SLO is an active player in modulating tau metabolic pathway(s) important for the development of tau pathology. However, in order for these results to have a translational value, it still remains to be established whether pharmacological inhibition of this source of pro-inflammatory mediators would result in an improvement of the phenotype of the P301S mice.

With this goal in mind, herein we investigated the effect of chronic pharmacologic inhibition of SLO with zileuton, a selective and irreversible SLO inhibitor (Riccioni, Di Ilio, Conti, Theoharides & D’Orazio, 2004). At the end of the study, compared with the controls, mice receiving the drug manifested a significant reduction in neuroinflammation and tau phosphorylation, which was associated with improvement in working memory and restoration of synaptic integrity.

2 | RESULTS

2.1 | Zileuton ameliorates learning and memory deficits of P301S mice

Starting at 3 months of age, P301S and wild type (WT) mice were administered with zileuton or vehicle for 7 months, after which they were assessed in two behavioral paradigms: the Y-maze and the Morris water maze. No differences were observed between the four groups of mice (wild-type, wild-type-zileuton, P301S, P301S-zileuton) in regard to their general motor activity which was assessed by the total number of arm entries in the arms of the maze (Figure 1a). However, when we counted the number of alternations in the same paradigm, we observed that P301S tau transgenic mice controls had a less number of alternations, resulting in a significantly lower percentage compared to the WT group. By contrast, the P301S mice receiving zileuton had a higher number of alternations, which were comparable to the WT group, suggesting an improvement of their working memory (Figure 1b). No significant differences in this behavioral paradigm were observed between males and females for all groups (not shown).

Thereafter, mice were tested for reference spatial memory function using the Morris water maze. In these studies, we performed visible platform training followed by hidden platform testing with four probe trials per day. All mice in each group were similarly proficient swimmers, able to locate the visible platform, and no difference in the average swimming speed was observed among the different groups (Figure 1d). In the training phase, although the P301S mice took more time to reach the platform by day four, all of them reached the training criterion (Figure 1c). However, compared with the treated group, P301S mice receiving vehicle performed significantly worse. As shown in Figure 1e,f, in the probe trial, untreated P301S mice showed significant lower number of entries and crosses of the target platform and took significantly more time to reach the target zone when compared with WT mice. By contrast, P301S mice treated with zileuton had the number of crosses of the platform zone and the latency to reach the platform zone similar to the WT mice (Figure 1e,f). No effect of zileuton on any of these behavioral paradigms was observed in the WT mice (Figure 1c–f). No significant differences in this paradigm were observed between males and females for all four groups of mice (data not shown).

2.2 | Inhibition of SLO activation reduces tau phosphorylation

First, to confirm compliance with the drug regimen implemented, we investigated the effect that chronic administration of zileuton had on the SLO enzymatic pathway. The dose of the drug selected in this study was based on our previous work, showing that this concentration of drug significantly reduces SLO activation (Chu et al., 2013). As shown in Figure 2a, no significant differences were observed between the P301S control group and P301S mice receiving zileuton when steady-state levels of brain SLO protein were assayed. By contrast, we found that compared with their controls, brains from P301S mice receiving zileuton had a significant reduction in leukotriene B4 (LTB4) levels, the major metabolic product of SLO enzymatic activation (Figure 2c).

Next, we assessed the effect of SLO pharmacological inhibition on tau levels and phosphorylation. As shown in Figure 2d, although we did not observe any changes in the levels of total soluble tau between the two groups, compared with the control mice, the zileuton-treated P301S mice showed a significant decrease in its phosphorylated forms at epitopes Thr231/Thr235 (as recognized by the antibody AT180), Thr181 (as recognized by AT270), and Ser396/Ser404 (as recognized by the antibody PHF1). By contrast, no significant changes were observed at epitopes Ser396 (as recognized by the antibody PHF13) and Ser202/Thr205 (as recognized by the antibody AT8) (Figure 2d,e).

Additionally, we explored the effect of SLO pharmacologic blockade on levels of insoluble tau fraction. Compared to the P301S control mice, brain cortex homogenates from P301S mice receiving zileuton showed a significant decrease in the sarkosyl-soluble fraction of total tau as recognized by the HT7 antibody (Figure 3a,b).

Finally, we investigated the molecular mechanism responsible for the zileuton-dependent changes in tau phosphorylation. As shown in Figure 3, no significant differences between the two groups were observed when brain cortices of these mice were assayed for levels of total and phosphorylated glycogen synthase kinase 3-α (GSK3-α) and GSK3-β. By contrast, we found that compared with the P301S controls, the zileuton-treated P301S mice...
had a significant decrease in the co-activators of the cdk5 kinase pathways (p35 and p25), suggesting a reduction in the activity of this kinase (Figure 3c,d).

2.3 | Effect of zileuton on synaptic integrity

Like in human tauopathy, another aspect of the phenotype of this model is an impairment of synaptic integrity (Pozueta, Lefort & Shelanski, 2013), for this reason, next we examined the effect of zileuton on synaptic integrity markers. Compared with the P301S control group, zileuton-treated transgenic tau mice displayed a significant increase in the steady-state levels of two key synaptic proteins: synaptophysin and postsynaptic density protein-95 (PSD-95) (Figure 4a,b). By contrast, no changes were observed between the two groups of mice when the steady-state levels of the dendritic protein MAP2 were assessed (Figure 4a,b).

2.4 | Effect of zileuton on neuroinflammation

Next, we assessed whether zileuton influenced neuroinflammation in these mice. As shown in Figure 4, when we compared brains from control mice with the P301S mice chronically treated with zileuton, we observed a statistically significant reduction in the steady-state levels of the glial fibrillary protein (GFAP) and cluster of differentiation 45 (CD45), markers of astrocytes, and microglial cell activation, respectively (Figure 4c,d).
The current study demonstrates that chronic pharmacologic blockade of 5LO enzymatic activity by zileuton in the central nervous system of a relevant transgenic mouse model of human tauopathy, the P301S mice, by preventing leukotriene formation reduces neuroinflammation and thus lowers tau phosphorylation, improves behavioral deficits, and ameliorates synaptic pathology. Taken together, these data add experimental support to the notion that this enzymatic pathway and its metabolic products play a direct role in the development of the entire tau pathological phenotype, and for this reason, it is a viable therapeutic target with true modifying-disease potential for the treatment human tauopathies.

The 5LO enzymatic pathway, which upon activation produces potent lipid inflammatory mediators called leukotrienes, has recently emerged as a novel player actively involved in AD-like neurodegeneration and as a viable therapeutic target (Chu & Pratico, 2016; Joshi & Praticò, 2015). Previously, we have demonstrated that its genetic absence modulates the functional and pathologic phenotype of a relevant mouse model of human tauopathy, the P301S mice (Vagnozzi et al., 2017). However, in order for these findings to be translatable into a preclinical setting, it is of paramount importance to show that administration of a drug that blocks the activation of this protein enzyme is beneficial and reproduces the positive outcomes we observed by implementing the genetic approach.

With this goal in mind, we chronically administered zileuton, an orally available and irreversible 5LO activation inhibitor (Steinhilber & Hofmann, 2014), to the P301S mice starting at 3 months of age. After 7 months of treatment, we found that P301S mice receiving zileuton when compared with P301S receiving vehicle displayed a significant improvement in their memory as shown in the Y-maze paradigm, which by recording spontaneous alternation behavior assesses short-term and working memory. Additionally, the treated mice outperformed the untreated ones in another behavioral paradigm, which measures learning and spatial memory: the Morris water maze. Importantly, we observed that compared with the group of
mice receiving vehicle, P301S mice chronically treated with zileuton manifested a significant amelioration of their spatial memory deficits, as shown in the higher number of platform crossing as well as a reduced latency to cross the platform area. No effect of the treatment was observed for both behavioral parameters in the WT mice, suggesting a transgene specific effect of the drug.

As for any pharmacological study, when using a probe drug, it is always very important to check for either drug levels in the organ target, or target engagement to assure for compliance with the drug regimen. In our study, mice were exposed to the drug ad libitum as it was dissolved in their drinking water, and based on the daily consumption of water of approximately 5 ml, we were confident that, as in our previous studies, they were exposed to a therapeutic dose of zileuton (Chu et al., 2013). To confirm compliance with the treatment as well as target engagement, we assessed brain levels of LTB4, the major metabolic product of 5LO enzymatic activation, and found that indeed it was reduced by almost 80%.

By pharmacologically blocking 5LO enzymatic activation and the source of this potent pro-inflammatory lipid mediator-like LTB4 (Bennett & Gilroy, 2016), we also observed a significant reduction in neuroinflammation as demonstrated by a decrease in both GFAP and CD45 levels which are markers of astrocytes and microglia cells activation, respectively.

Besides the improvement in memory, learning and neuroinflammation, we found that pharmacologic inhibition of 5LO enzymatic activity modulated tau metabolism. In particular, we observed that compared with controls, P301S-treated mice had significantly decreased levels of tau phosphorylation at specific epitopes, which have been implicated in the development of the tau neurofibrillary tangles pathology (Kelleher, Garwood, Hanger, Anderton & Noble, 2007; Weaver, Espinoza, Kress & Davies, 2000). By contrast, no differences between the two groups of mice were observed when the levels of total soluble tau were measured. Interestingly, we found that zileuton-treated mice had a significant decrease in the insoluble fraction of total tau, suggesting a change in its solubility and conformation status.

In search for the molecular mechanism involved in the zileuton-dependent effect on tau phosphorylation, we assayed some of the enzymatic pathways (i.e., kinases) that have been suggested to play a functional role in this aspect of tau metabolism. Among the different

**FIGURE 3** Involvement of the cdk5 kinase pathway in the leukotriene-dependent effect on tau phosphorylation. Starting at 3 months of age, P301S mice were randomized to receive zileuton or vehicle until 10 months of age and then euthanized, and brain was extracted for biochemistry. (a) Representative Western blot analyses for insoluble total tau fraction (HT7) in brain cortex homogenates from P301S and P301S-zileuton mice. (b) Densitometric analysis of the immunoreactivity to the antibody presented in panel A (*p < .01). (c) Representative Western blot analyses for cdk5, p35, p25, GSK3α, GSK3β, p-GSK3α, and p-GSK3β, in brain cortex homogenates from P301S and P301S-zileuton. (d) Densitometric analysis of the immunoreactivity to the antibody presented in the previous panel (*p < .01). Values represent mean ± SEM (n = 10 per group)
kinases investigated, we observed that only the cdk5 kinase pathway was significantly changed following the pharmacologic blockade of 5LO activation, suggesting a specific involvement for this kinase in the biological effect.

It is known that the development of tau pathology results in biochemical and functional manifestations of synaptic deficits, which are typically represented by altered levels of pre- and postsynaptic protein markers (Alldred, Duff & Ginsberg, 2012; Moreno et al., 2016; Yin et al., 2016). In our study, we observed that compared with the control group, P301S mice chronically treated with zileuton had a significant increase in the levels of synaptophysin and postsynaptic density protein-95, two distinct markers of synaptic integrity. This result suggests an improvement of this important functional and biological aspect for general memory and learning secondary to 5LO irreversible pharmacological blockade.

4 | CONCLUSIONS

In summary, our study provides further experimental support for the active role that the leukotrienes pathway plays in the pathogenesis of a model of pure tauopathy, in which it directly influences tau phosphorylation levels and solubility, memory and learning, and synaptic integrity. These new findings represent the successful completion of the initial step for the preclinical evaluation and development of this class of drugs, the 5LO inhibitors, as a novel and potentially disease-modifying agents for neurodegenerative diseases characterized by the accumulation of highly phosphorylated microtubule-associated protein tau.

5 | EXPERIMENTAL PROCEDURES

5.1 | Animals

All animal procedures were approved by the Institutional Animal Care and Usage Committee, in accordance with the US National Institutes of Health guidelines. The P301S mice (PS19 line) express human mutant microtubule-associated protein tau, MAPT, driven by the mouse prion protein promoter (Yoshiyama et al., 2007). The wild-type (WT) mice are age-matched C57BL6/SJL mice. All the animals were kept in a pathogen-free environment on a 12-hr light/dark cycle and fed a normal chow and water ad libitum. Two separate groups of 3-month-old WT and P301S mice were randomized to receive zileuton (200 mg/L) or vehicle in their drinking water three times per week over 7 months.
(n = 10 per group; 5 males, 5 females). This amount of the drug was selected based on our previous work where we showed that it significantly reduced 5LO activation (Chu et al., 2013). After the treatment period and at 10 months of age, the mice underwent behavioral tests as described below. A week later, they were euthanized, and brain was removed, gently rinsed in cold 0.9% PBS, and immediately dissected into two halves. One half was immediately stored at −80°C for biochemistry; the other half was fixed in 4% paraformaldehyde in PBS, pH 7.4, for immunohistochemistry studies.

5.2 | Behavioral tests

All the animals were handled for at least 3–4 days prior to testing. They were tested in the Y-maze and Morris water maze in random order and the experimenter conducting the tests was unaware of the genotype or treatment.

5.3 | Y-maze

The Y-maze apparatus consisted of three arms of 32 cm long and 610 cm wide with 26-cm walls (San Diego Instruments, San Diego, CA, USA). Testing was always performed in the same room and at the same time to ensure environmental consistency as previously described (Di Meco, Lauretti, Vagnozzi & Praticò, 2014; Giannopoulos et al., 2013). Briefly, each mouse was placed in the center of the Y-maze and allowed to explore freely during a 5-min session as a measure of spontaneous alternating behavior. The sequence and total number of arms entered were video-recorded. An entry into an arm was considered valid if all four paws entered the arm. An alternation was defined as three consecutive entries into three different arms (1, 2, 3, or 2, 3, 1, etc.). Percentage of alternation was calculated using the following formula: (total alternation number/total number of entries − 2 × 100).

5.4 | Morris water maze

To perform the Morris water maze (MWM), we used a white circular plastic tank (122 cm in diameter, walls 76 cm high), filled with water maintained at 22±2°C, and made opaque by the addition of a non-toxic white paint, as previously described (Di Meco et al., 2014; Giannopoulos et al., 2013). Mice were trained on four consecutive days to find a Plexiglas platform submerged in water from four different starting points. If they failed to find the platform within 60 s, they were manually guided to the platform and allowed to remain there for 15 s. Mice were trained to reach a training criterion of 60 s (escape latency). Mice were assessed in the probe trial, which consisted of a free swim lasting for 60 s without the platform, 24 hr after the last training session. Animals’ performances were monitored using Any-Maze™ Video Tracking System (Stoelting Co., Wood Dale, IL, USA) which provided data for the acquisition parameters (latency to find the platform and distance swim and) and the probe trial parameters (number of entries in the target platform zone of the platform and time in quadrants).

5.5 | Western blot analyses

RIPA (radio immunoassay precipitation) extracts from mouse brain homogenates were used for Western blot analyses as previously described (Di Meco et al., 2014; Giannopoulos et al., 2013). Briefly, samples were electrophoresed on 10% Bis–Tris gels or 3%–8% Tris–acetate gel (Bio-Rad, Richmond, CA, USA), transferred onto nitrocellulose membranes (Bio-Rad), and then incubated overnight at 4°C with the appropriate primary antibodies; anti-5LO [dilution: 1:200] (Santa Cruz, Dallas, TX, USA), anti-hHT7 [1:200] (Thermo, Waltham, MA, USA), anti-AT8 [1:100] (Thermo), anti-AT180 [1:200] (Thermo); anti-AT270 [1:200] (Thermo), anti-PHF1 (generous gift of Dr. Peter Davies); anti-PHF13 [1:100] (Thermo), anti-SYP [1:300] (Santa Cruz), anti-PSD95 [1:200] (Thermo), anti-MAP2 [1:1,000] (Millipore), anti-GSK3α/β [1:100] (Cell Signaling, Danvers, MA, USA), anti-pGSK3α/β [1:100] (Cell Signaling), anti-cdk5 [1:200] (Santa Cruz), anti-p35/p25 [1:100] (Santa Cruz), anti-GFAP (Santa Cruz), anti-CD45 [1:100] (Thermo) and anti-Beta actin [1:500] (Santa Cruz). After three washings with T-TBS (pH7.4), membranes were incubated with IRDye 800CW-labeled secondary antibodies (LI-COR Bioscience, Lincoln, NE, USA) at room temperature for 1 hr. Signals were developed with Odyssey Infrared Imaging Systems (LI-COR Bioscience). β-Actin was always used as internal loading control.

5.6 | Sarkosyl insolubility assay

The assay for insoluble tau was performed as previously described (Li, Barrero, Merali & Praticò, 2017). Briefly, ultracentrifugation and sarkosyl extraction (30 min in 1% sarkosyl) were used to obtain soluble and insoluble fractions of tau from brain homogenates. Insoluble fractions were washed one time with 1% sarkosyl and then immunoblotted with the HT7 antibody.

5.7 | LTb4 assay

RIPA extracts from mouse brain homogenates were assayed for LTb4 levels using a specific LTb4 ELISA Kit (Enzo Life Sciences, Farmingdale, NY, USA) and following the instructions of the manufacturer (Di Meco et al., 2014; Giannopoulos et al., 2013).

5.8 | Data analysis

One-way analysis of variance (ANOVA), unpaired Student’s t test (two-sided), and Bonferroni multiple comparison tests were performed using Prism 5.0 (GraphPad Software, La Jolla, CA, USA). All data are presented as mean ± standard error of the mean. Significance was set at p < .05.

ETHICS APPROVAL

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All experiments were approved by the Institutional Animal Care and Use Committee.
CONFLICT OF INTEREST

The authors have no conflicting financial interest to disclose.

AUTHORS’ CONTRIBUTION

PFG and DP designed the study. PFG and JC carried out the experiments, performed the measurement, and analyzed the data. PFG and DP drafted the manuscript. All authors read and approved the final manuscript.

REFERENCES

Alldred, M. J., Duff, K. E., & Ginsberg, S. D. (2012). Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiology of Diseases, 45, 751–762. https://doi.org/10.1016/j.nbd.2011.10.022

Arendt, T., Steier, J. T., & Holzer, M. (2016). Tau and tauopathies. Brain Research Bulletin, 126, 238–292. https://doi.org/10.1016/j.brresbull.2016.08.018

Bennett, M., & Gilroy, D. W. (2016) Lipid mediators in inflammation. Microbiology Spectrum, 4(6). https://doi.org/10.1128/microbiolspec.MCHD-0035-2016

Chu, J., Giannopoulos, P. F., Ceballos-Diaz, C., Golde, T. E., & Praticò, D. (2012). 5-lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Annals of Neurology, 72, 442–454. https://doi.org/10.1002/ana.23642

Chu, J., Li, J. G., & Praticò, D. (2013). Zileuton improves memory defects, amyloid and tau pathology in a mouse model of Alzheimer’s disease with plaques and tangles. PLoS One, 8, e70991. https://doi.org/10.1371/journal.pone.0070991

Chu, J., & Praticò, D. (2016). The 5-lipoxygenase as modulator of Alzheimer’s γ-secretase and therapeutic target. Brain Research Bulletin, 126, 207–212. https://doi.org/10.1016/j.brresbull.2016.03.010

Di Meco, A., Laurenti, E., Vagnozzi, A., & Praticò, D. (2014). Zileuton restores memory impairments and reverses amyloid and tau pathology in aged AD mice. Neurobiology of Aging, 35(11), 2458–2464. https://doi.org/10.1016/j.neurobiolaging.2014.05.016

Giannopoulos, P. F., Chu, J., Joshi, Y. B., Sperow, M., Li, J. G., Kirby, L. G., & Praticò, D. (2013). 5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer’s disease. Biological Psychiatry, 74, 348–356. https://doi.org/10.1016/j.biopsych.2013.04.009

Giannopoulos, P. F., Chu, J., Joshi, Y. B., Sperow, M., Li, J. G., Kirby, L. G., & Praticò, D. (2014). Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer’s disease. Molecular Psychiatry, 19, 511–518. https://doi.org/10.1038/mp.2013.23

Giannopoulos, P. F., Chu, J., Sperow, N., Li, J. G., Yu, W. H., Kirby, L. G., … Praticò, D. (2015). Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biological Psychiatry, 78, 693–701. https://doi.org/10.1016/j.biopsych.2015.01.015

Giannopoulos, P. F., Joshi, Y. B., & Praticò, D. (2014). Novel lipid signaling pathways in Alzheimer disease pathogenesis. Biochemical Pharmacology, 88(4), 560–564. https://doi.org/10.1016/j.bcp.2013.11.005

Giannopoulos, P. F., & Praticò, D. (2015). Alzheimer’s disease. In C. R. Martin, V. Reddy (Eds.), Diet nutrition in dementia and cognitive disorders (pp. 13–21). London, UK: Elsevier Publisher. https://doi.org/10.1016/B978-0-12-407824-6.00002-1

Ishizawa, K., & Dickson, D. W. (2001). Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. Journal of Neuropathology and Experimental Neurology, 60, 647–657. https://doi.org/10.1093/jnen/60.6.647

Joshi, Y., Chu, J., & Praticò, D. (2013). Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in the 3xTg mice. Aging Cell, 12(4), 706–711. https://doi.org/10.1111/acel.12096

Joshi, Y., & Praticò, D. (2015). The 5-lipoxygenase pathway: Oxidative and inflammatory contributions to the Alzheimer’s disease pathology. Frontiers in Cellular Neuroscience, 8(436), 1–8.

Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., & Noble, W. (2007). Kinase activities increase during the development of tauopathy in htau mice. Journal of Neurochemistry, 103, 2256–2267. https://doi.org/10.1111/j.1471-4159.2007.04930.x

Laurent, C., Dorothee, G., Hunot, S., Martin, E., Monnet, Y., Duchamp, M., … Leboucher, A. (2007). Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain, 140, 184–200.

Li, J. G., Barrero, C., Merali, S., & Praticò, D. (2017) Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype. Scientific Reports, 7, 46002. https://doi.org/10.1038/srep46002

Moreno, H., Morfini, G., Buitrago, L., Ujlaki, G., Choi, S., Yu, E., … Linus, R. R. (2016). Tau pathology-mediated presynaptic dysfunction. Neuroscience, 325, 30–38. https://doi.org/10.1016/j.neuroscience.2016.03.044

Pozueta, J., Lefort, R., & Shelski, M. L. (2013). Synaptic changes in Alzheimer’s disease and its models. Neuroscience, 251, 51–65. https://doi.org/10.1016/j.neuroscience.2012.05.050

Riccioni, G., Di Ilia, C., Conti, P., Theoharides, T. C., & D’Orazio, N. (2004). Advances in therapy with anti-leukotriene drugs. Annals of Clinical and Laboratory Science, 34, 379–387.

Spillantini, M. G., & Goedert, M. (2013). Tau pathology and neurodegeneration. The Lancet Neurology, 12, 609–622. https://doi.org/10.1016/S1474-4422(13)70090-5

Steinhilber, D., & Hofmann, B. (2014). Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic & Clinical Pharmacology & Toxicology, 114(1), 70–77. https://doi.org/10.1111/bcpt.12114

Vagnozzi, A. N., Giannopoulos, P. F., & Praticò, D. (2017). The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Translational Psychiatry, 7(12), 1288. https://doi.org/10.1038/s41398-017-0017-2

Weaver, C. L., Espinosa, M., Kress, Y., & Davies, P. (2000). Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiology of Aging, 21, 719–727. https://doi.org/10.1016/S0197-4580(00)00157-3

Yin, Y., Gao, D., Wang, Y., Wang, Z. H., Wang, X., Ye, J., … Wang, J. Z. (2016) Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling. Proceedings of the National Academy of Sciences of the United States of America, 113(26), E3773–E3781. https://doi.org/10.1073/pnas.1604519113

Yoshiiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saida, T. C., … Lee, V. M. (2007). Synapse loss and microglia activation precede tangles in a P301S tauopathy mouse model. Neuron, 53, 337–351. https://doi.org/10.1016/j.neuron.2007.01.010

How to cite this article: Giannopoulos PF, Chu J, Praticò D. Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice. Aging Cell. 2018;17:e12759. https://doi.org/10.1111/acel.12759